Risk of cardiovascular disease and cancer in patients initiating JAK versus IL-4/-13 inhibitors for atopic dermatitis

Sizheng Zhao*, Gema Hernandez, Uazman Alam

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalInternational Journal of Dermatology
DOIs
Publication statusPublished - 28 Apr 2025

Keywords

  • eczema
  • cardiovascular disease
  • malignancy
  • tofacitinib
  • upadacitinib
  • dupilumab

Cite this